According to a new report by Polaris Market Research, the global peptide-based cancer therapeutics market was valued at USD 8.58 billion in 2019 and is projected to reach USD 17.18 billion by 2027, expanding at a CAGR of 9.1% over the forecast period. Growth is underpinned by the rising global prevalence of cancer, innovations in peptide-based treatment approaches, and increasing pharmaceutical R&D investment across key end-use regions.

What Is Driving Peptide-Based Cancer Therapeutics Market Growth?

Demand is climbing as the lack of tumor selectivity in conventional cancer therapeutics converges with growing drug resistance among patients. Pharmaceutical companies are prioritizing high target-selectivity treatment approaches, pushing peptide-based cancer therapeutics adoption across oncology centers worldwide. Polaris analysts note that combination therapies pairing peptide treatments with checkpoint inhibitors are improving patient outcomes, positioning the segment for sustained growth through 2027, with lung cancer emerging as the largest revenue contributor and North America posting the fastest incremental gains.

Key Trends Shaping the Peptide-Based Cancer Therapeutics Industry

Genomics and Bioinformatics-Driven Discovery

Recent computing advancements in genomics and bioinformatics are enabling discovery of new antigen-derived personalized vaccines, reflecting accelerating technology advancement in peptide-based drug development.

Combination Therapy With Checkpoint Inhibitors

Growing use of peptide therapies alongside checkpoint inhibitors is emerging as a preferred treatment pathway, improving patient outcomes and reshaping the competitive landscape for oncology drug developers.

Rising Investment Despite Manufacturing and Bioavailability Hurdles

Pharmaceutical companies are intensifying R&D investment even as high manufacturing costs, limited oral bioavailability, and low resistance to serum protease cleavage continue to shape the market outlook for next-generation peptide formulations.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market 

Market Segmentation: Breaking Down the Peptide-Based Cancer Therapeutics Market

Polaris segments the peptide-based cancer therapeutics market by drug type, cancer type, mode of mechanism, and distribution channel, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Drug Type

The Bortezomib segment accounted for the largest share in 2019, supported by higher drug sales, high efficacy, and low side effects as a proteasome inhibitor indicated for multiple myeloma and cell lymphoma. Goserelin and Leuprorelin round out the leading formulations as pharmaceutical companies expand hormone-based peptide portfolios.

By Cancer Type

Lung cancer accounted for the majority of revenue share in 2019 and is likely to maintain its lead over the study period, driven by rising incidence linked to air pollution, occupational exposure, and smoking — the WHO recorded 1.8 million global lung cancer deaths in 2018 alone. Breast and colorectal cancer applications are also gaining share as diagnostic rates rise across emerging economies.

By Distribution Channel

Hospital pharmacies remain the dominant distribution channel, supported by the clinical oversight required for peptide-based oncology treatment, while retail and online pharmacies are gaining share as personalized-medicine adoption expands access beyond hospital settings.

Regional Outlook: Where Is Peptide-Based Cancer Therapeutics Growing Fastest?

North America led the market in 2019, supported by rising cancer research investment and 1,688,780 recorded cancer cases in 2017 per the American Cancer Society and National Center for Health Statistics, while Asia Pacific is positioned for strong growth through 2027, driven by rising personalized-medicine adoption in China, Japan, South Korea, and India. Within North America, the United States remains the largest single market on the strength of its cancer research infrastructure; within Asia Pacific, China and India are primary growth engines, with China recording more than 4.3 million new cancer cases annually. Latin America rounds out the landscape, with lung cancer accounting for more than 75,300 regional deaths each year.

Competitive Landscape: Leading Peptide-Based Cancer Therapeutics Companies

Key players profiled in the report include AstraZeneca PLC, Pfizer Inc., Amgen, Inc., and Johnson & Johnson, who are focusing on R&D investment, combination-therapy pipelines, and strategic partnerships to strengthen market position across the Bortezomib and lung-cancer segments outlined above. Additional profiled companies include Abbott, Allergan plc, Teva Pharmaceuticals, Takeda Pharmaceutical, AbbVie Inc., and Valeant Pharmaceuticals Inc., each expanding oncology portfolios to capture rising demand.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the peptide-based cancer therapeutics market, this report benchmarks market share, segment-level pricing, and forecast data — by drug type, cancer type, mode of mechanism, distribution channel, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking combination immunotherapy as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Synthetic Lubricants Market

Surgical Robots Market

Synthetic Leather Market

3D Motion Capture System Market

Superconducting Wire Market

Superconducting Wire Market

Digital Signage Market

CAR-T Cell Therapy Market

Concrete repair mortars market